垂直袖状胃切除术与Roux-en-Y胃旁路术治疗糖尿病的比较效果:基于理赔数据的队列研究
该研究利用美国商业保险理赔数据库,匹配1111例垂直袖状胃切除术(VSG)和922例Roux-en-Y胃旁路术(RYGB)的糖尿病患者,比较术后糖尿病药物停用情况。结果显示RYGB患者停用所有糖尿病药物的可能性更高(HR 0.80, 95%CI 0.72-0.88),且术后第2年下半年RYGB患者糖尿病药物总剂量较VSG低86%(32%, 140%)。
要点
- RYGB术后停用所有糖尿病药物的可能性高于VSG(HR 0.80, 95%CI 0.72-0.88)。
- 术后第2年下半年RYGB患者糖尿病药物总剂量较VSG低86%(32%, 140%)。
- 糖尿病患者在选择减重术式时应考虑RYGB在糖尿病结局上的潜在优势。
核心结论
- 在基于理赔数据的全国性减重手术糖尿病患者队列中,RYGB患者比VSG患者更可能停用所有糖尿病药物。
研究设计与样本
- 基于美国全国商业保险理赔数据库的回顾性队列研究,纳入2010至2016年接受VSG或RYGB的成人糖尿病患者。
- 匹配后队列包括1111例VSG和922例RYGB患者,匹配变量包括基线胰岛素使用、糖尿病药物总负担、年龄、糖尿病并发症及随访时长。
- 采用调整的Cox比例风险模型比较药物停用,采用双重差分分析比较术后2年内药物使用强度变化。
主要发现
- 匹配队列中16%患者年龄小于40岁,11%为60岁及以上,67%为女性,67%体重指数≥40 kg/m2,23%手术时使用胰岛素。
- VSG患者停用所有糖尿病药物的可能性低于匹配的RYGB患者(风险比0.80, 95%置信区间0.72-0.88)。
- 两组术后药物使用均大幅下降,但术后第2年下半年RYGB患者糖尿病药物总剂量较VSG低86%(32%, 140%)。
临床怎么用
- 对于合并糖尿病的减重手术候选者,可将RYGB在停药和降低药物剂量方面的潜在优势纳入术式选择的共同决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to compare diabetes outcomes following vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB). BACKGROUND: There are few comparative studies on diabetes outcomes after VSG and RYGB. METHODS: We used a US-wide commercial insurance claims database to identify adults with diabetes undergoing VSG or RYGB in 2010 to 2016. We matched patients on baseline insulin use, total diabetes medication burden, age, presence of diabetes complications, and follow-up duration, and used adjusted Cox proportional hazards models to compare diabetes medication discontinuation between procedures. We used difference-in-differences analyses to compare changes in medication use intensity up to 2 years after surgery. RESULTS: The matched cohort included 1111 VSG and 922 RYGB patients: 16% were younger than 40 years, 11% were 60 years or older, 67% were women, 67% had a body mass index of 40 kg/m2 or higher, and 23% were on insulin at the time of surgery. Thirteen percent were lost to follow-up at 1 year, and 30% at 2 years after surgery. Patients with VSG were less likely than matched RYGB patients to discontinue all diabetes medications (hazard ratio 0.80, 95% confidence interval 0.72-0.88). Although both groups had substantial decreases in medication use after surgery, RYGB patients had an 86% (32%, 140%) lower total diabetes medication dose than VSG by the second half of postoperative year 2. CONCLUSIONS: In a large claims-based, nationwide cohort of bariatric patients with diabetes, those undergoing RYGB were more likely to come off all medications than those undergoing VSG. Patients with diabetes should consider this potential benefit of RYGB when making informed decisions about obesity treatments.
引用
- Lewis KH, Arterburn DE, Zhang F, et al. Comparative Effectiveness of Vertical Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Diabetes Treatment: A Claims-based Cohort Study. Ann Surg. 2021. PMID: 31205064. doi:10.1097/SLA.0000000000003391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。